Fecal Microbiota Transplantation (FMT) Market Report 2026

Fecal Microbiota Transplantation (FMT) Market Overview

• Fecal Microbiota Transplantation (FMT) market size has reached to $0.91 billion in 2025 • Expected to grow to $1.27 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Rising Prevalence Of Gastrointestinal Disorders Growth In Fecal Microbiota Transplantation (FMT) Market • Market Trend: Advancements In Standardized Microbiota-Based Therapeutics • North America was the largest region in 2025.

What Is Covered Under Fecal Microbiota Transplantation (FMT) Market?

Fecal microbiota transplantation (FMT) is a medical procedure where a healthy donor's fecal material is transplanted into a recipient's gastrointestinal tract to restore the balance of beneficial microorganisms in the gut. This procedure is typically used to treat conditions where the gut microbiota is disrupted, such as recurrent clostridium difficile infection (CDI) that does not respond to standard treatments. The main types of fecal microbiota transplantation (FMT) are fermentation, fresh, and cryopreservation. Fermentation in Fecal Microbiota Transplantation (FMT) refers to the process by which gut bacteria break down complex carbohydrates and fibers in the gastrointestinal tract, producing short-chain fatty acids and other metabolites that promote gut health. Donor types include stool-derived, fecal-derived, and whole-microbiome derived, used to treat various conditions such as Clostridioides difficile infection, inflammatory bowel disease, metabolic syndrome, and others. It is administered through oral, rectal, nasogastric, and colon capsule routes. The end users include hospitals, specialty clinics, and others.

What Is The Fecal Microbiota Transplantation (FMT) Market Growth Forecast?

The fecal microbiota transplantation (fmt) market size is expected to see strong growth in the next few years. It will grow to $1.27 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing research into microbiome-based therapeutics, rising demand for standardized fmt formulations, expansion of indications beyond gastrointestinal diseases, growing investment in microbiome biotechnology, advancement in oral delivery technologies. Major trends in the forecast period include increasing standardization of donor screening protocols, rising adoption of cryopreserved fmt products, growing clinical acceptance beyond cdi treatment, expansion of capsule-based administration methods, enhanced focus on microbiome analytics.

Global Fecal Microbiota Transplantation (FMT) Market Segmentation

1) By Type: Fermentation, Fresh, Cryopreservation 2) By Donor Type: Stool-Derived, Fecal-Derived, Whole-Microbiome Derived 3) By Indication: Clostridioides Difficile Infection, Inflammatory Bowel Disease, Metabolic Syndrome, Other Indications 4) By Administration Route: Oral, Rectal, Nasogastric, Colon Capsule 5) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Fermentation: Fermented FMT Products, Fermented Capsules, Fermented Liquids, In-House Fermentation Techniques 2) By Fresh: Fresh Stool Samples, Fresh FMT Capsules, Fresh FMT Solutions for In-Hospital Use, Freshly Prepared FMT for Outpatient Use 3) By Cryopreservation: Cryopreserved Stool Samples, Cryopreserved FMT Capsules, Cryopreserved Liquid FMT, Long-Term Storage Solutions for Cryopreserved FMT

What Is The Driver Of The Fecal Microbiota Transplantation (FMT) Market?

The rising prevalence of gastrointestinal disorders is expected to propel the growth of the fecal microbiota transplantation (FMT) market going forward. Gastrointestinal (GI) disorders refer to a wide range of conditions that affect the gastrointestinal tract, which includes the esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. The rise in gastrointestinal disorders is due to increased stress, sedentary lifestyles, and higher consumption of processed foods. Fecal microbiota transplantation is used in gastrointestinal disorders to restore healthy gut bacteria, particularly for treating recurrent Clostridioides difficile infections. For instance, in 2023, according to Crohn's and Colitis Canada, a Canada-based non-profit organization, the number of people in Canada with IBD is increasing rapidly, from 322,600 in 2023 (0.8% of the population) to 470,000 in 2035 (1.1% of the population). In 2023, 11,000 people will be diagnosed (1 every 48 minutes), and by 2035, this will rise to 14,000 (1 every 38 minutes). Therefore, the rising prevalence of gastrointestinal disorders drives the growth of the fecal microbiota transplantation (FMT) industry.

Key Players In The Global Fecal Microbiota Transplantation (FMT) Market

Major companies operating in the fecal microbiota transplantation (fmt) market are Ferring Pharmaceuticals, Johns Hopkins Medicine, Seres Therapeutics, Taconic Biosciences, Enterome, Rebiotix Inc, Finch Therapeutics Group Inc, Locus Biosciences, Yeda Research and Development Co. Ltd, Microbiotica Limited, CosmosID Inc, AOBiome, Synthetic Biologics Inc., Osel Inc., OpenBiome, Asia Microbiota Bank, Taymount Clinic, MicroBiome Therapeutics LLC, MaaT Pharma SA, Kallyope

Global Fecal Microbiota Transplantation (FMT) Market Trends and Insights

Major companies operating in the fecal microbiota transplantation (FMT) market are focusing on incorporating standardized microbiota-based therapies such as fecal microbiota spores, live-brpk to enhance safety, patient compliance, treatment consistency, and scalability. Fecal microbiota spores, live-brpk are highly processed donor-derived microbial spores manufactured under strict screening and purification procedures to restore healthy gut microbiota with controlled dosing and reduced infection risk. For instance, in April 2023, Seres Therapeutics, a US-based microbiome therapeutics company, received FDA approval for VOWST, a fecal microbiota spores, live-brpk therapy designed to prevent recurrence of Clostridioides difficile infection in adults, featuring oral capsule delivery, defined microbial spore composition, and rigorous pathogen-screening protocols. VOWST improves treatment convenience, safety, and commercial scalability in the FMT sector.

What Are Latest Mergers And Acquisitions In The Fecal Microbiota Transplantation (FMT) Market?

In September 2024, Metagen Therapeutics, Inc., a Japan-based biotechnology startup, partnered with JSR Corporation to establish an investigational-drug manufacturing facility for fecal microbiota transplantation (FMT) drugs. With this partnership, Metagen Therapeutics and JSR aim to produce and scale up oral FMT drug candidates, enable the start of preclinical and clinical trials, improve manufacturing and quality-control of microbiome-based therapies, and accelerate delivery of FMT-derived treatments to patients. JSR Corporation is a Japan-based materials and life-sciences company with expertise in advanced materials and biologics manufacturing and is contributing manufacturing infrastructure and development capabilities for microbiome medicines.

Regional Outlook

North America was the largest region in the fecal microbiota transplantation (FMT) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Fecal Microbiota Transplantation (FMT) Market?

The fecal microbiota transplantation (FMT) market consists of revenues earned by entities by providing services such as donor screening and testing, microbiome assessment, stool collection, processing and preparation, endoscopic delivery, clinical monitoring, and symptom management. The market value includes the value of related goods sold by the service provider or included within the service offering. The fecal microbiota transplantation (FMT) market also includes sales of oral capsules, colonoscopy-based FMT, nasogastric or nasoduodenal tube and lyophilized (freeze-dried) stool. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Fecal Microbiota Transplantation (FMT) Market Report 2026?

The fecal microbiota transplantation (fmt) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the fecal microbiota transplantation (fmt) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.